A multicentre phase II trial to determine the efficacy of RAD 001 (everolimus, Afinitor) as second line therapy in patients with transitional cell carcinoma (TCC) of the urothelium which failed or progressed after first line chemotherapy.

Trial Profile

A multicentre phase II trial to determine the efficacy of RAD 001 (everolimus, Afinitor) as second line therapy in patients with transitional cell carcinoma (TCC) of the urothelium which failed or progressed after first line chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 May 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms AFINIVEST
  • Most Recent Events

    • 02 Jun 2015 Primary endpoint (Progression-free survival rate) has been met, according to abstract presented at ASCO 2015.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO 2015).
    • 02 Jun 2015 Status changed from recruiting to completed, as reported in ASCO 2015 abstract.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top